tixagevimab / cilgavimab

This medicine is authorised for use in the European Union.


Evusheld is a medicine used to prevent COVID-19 in adults and adolescents (from 12 years of age weighing at least 40 kilograms). It is also used to treat COVID-19 in adults and adolescents who do not require supplemental oxygen and who are at increased risk of the disease becoming severe.

Evusheld contains two active substances, tixagevimab and cilgavimab.

This EPAR was last updated on 18/08/2023

Authorisation details

Product details
Agency product number
Active substance
  • tixagevimab
  • cilgavimab
International non-proprietary name (INN) or common name
  • tixagevimab
  • cilgavimab
Therapeutic area (MeSH)
COVID-19 virus infection
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
AstraZeneca AB
Date of issue of marketing authorisation valid throughout the European Union
Contact address

151 85 Sodertalje

Product information

16/08/2023 Evusheld - EMEA/H/C/005788 - PSUSA/00010992/202211

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Not yet assigned

Therapeutic indication

Prevention of COVID-19.

Assessment history

How useful was this page?

Add your rating
3 ratings
1 rating
1 rating